Adams Diversified Equity Fund Inc. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Adams Diversified Equity Fund Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 32.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 21,700 shares of the biopharmaceutical company’s stock after selling 10,600 shares during the period. Adams Diversified Equity Fund Inc.’s holdings in Regeneron Pharmaceuticals were worth $22,812,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of REGN. International Assets Investment Management LLC raised its holdings in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Capital International Investors raised its holdings in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after buying an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock valued at $868,757,000 after buying an additional 184,561 shares during the period. TD Asset Management Inc raised its holdings in Regeneron Pharmaceuticals by 162.9% in the 1st quarter. TD Asset Management Inc now owns 269,511 shares of the biopharmaceutical company’s stock valued at $259,402,000 after buying an additional 166,998 shares during the period. Finally, Swedbank AB purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at about $129,257,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $927.33 on Wednesday. The company’s 50 day simple moving average is $1,077.78 and its 200-day simple moving average is $1,041.48. The firm has a market cap of $102.23 billion, a PE ratio of 24.56, a price-to-earnings-growth ratio of 3.20 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 12-month low of $772.84 and a 12-month high of $1,211.20. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. Regeneron Pharmaceuticals’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period last year, the firm posted $8.79 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.6 EPS for the current year.

Analyst Ratings Changes

REGN has been the subject of several research reports. Evercore ISI dropped their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,137.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $1,260.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 22nd. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, October 22nd. Finally, Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,101.00.

Insider Transactions at Regeneron Pharmaceuticals

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at $4,498,280. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the completion of the sale, the vice president now directly owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.